MICC is an acronym telehealth weight-loss programs use for a compounded injectable blend: Methionine, Inositol, Choline, and Cyanocobalamin (vitamin B12). The formulation is marketed as a lipotropic injection, lipotropic meaning substances that influence how the liver processes and mobilizes fat. MICC is not a GLP-1 drug and does not replicate incretin appetite suppression. Instead, it sits alongside GLP-1 therapy as a metabolic adjunct for patients whose providers want to support hepatic fat handling, methylation pathways, and energy during aggressive calorie deficits.
Interest in MICC surged as GLP-1 adoption expanded. Weekly semaglutide and tirzepatide drive substantial weight loss, but patients often report fatigue, brain fog, or stalled progress when protein intake drops or liver fat mobilization lags behind rapid scale changes. MICC addresses a different layer of the metabolic stack than metformin ER or injectable incretins, micronutrient and lipotropic support rather than insulin sensitization or central appetite control.
What each component does
Methionine is an essential sulfur-containing amino acid and a precursor to S-adenosylmethionine (SAMe), the body's primary methyl donor. Methionine participates in phosphatidylcholine synthesis and hepatic fat export. In lipotropic injection lore, dating to mid-20th-century weight-clinic practice, methionine was combined with choline to reduce hepatic steatosis risk during very-low-calorie protocols. Modern obesity medicine rarely relies on methionine alone for weight loss, but the mechanistic rationale persists: support liver processing of mobilized triglycerides when fat mass drops quickly.
Inositol (often myo-inositol in compounded formulas) is a carbocyclic sugar involved in insulin signaling, phospholipid synthesis, and cellular second-messenger pathways. Inositol has independent evidence in polycystic ovary syndrome and insulin resistance at oral gram-scale doses. In MICC injections, inositol is present at smaller parenteral amounts as part of a bundled lipotropic cocktail rather than as a standalone PCOS intervention.
Choline is an essential nutrient for acetylcholine synthesis and a required precursor for very-low-density lipoprotein (VLDL) assembly in the liver. Without adequate choline, hepatic fat can accumulate, a concern when patients eat sharply reduced calories and lower dietary choline intake. Choline bitartrate or chloride salt forms appear in compounded MICC vials.
Cyanocobalamin (B12) supports erythropoiesis, neurologic function, and methionine synthase activity. B12 deficiency can cause fatigue and cognitive symptoms that overlap with GLP-1 side effects and rapid weight-loss malnutrition. Adding B12 to MICC serves both lipotropic synergy and symptomatic energy support, though patients with documented deficiency may need higher oral or intramuscular B12 doses than MICC alone provides.
How MICC differs from Lipo-Mino stacks
Compounding pharmacies also offer expanded lipotropic blends, sometimes labeled Lipo-Mino, that add L-carnitine, B6 (pyridoxine), and B-complex vitamins to the MICC backbone. L-carnitine shuttles long-chain fatty acids into mitochondria for beta-oxidation. CLYR offers both MICC + B12 and Lipo-Mino + L-Carnitine as distinct SKUs. MICC is the leaner four-ingredient formula; Lipo-Mino is the broader metabolic cocktail. Providers choose based on patient tolerance, injection volume limits, and whether carnitine-specific support is clinically relevant.
Evidence and expectations
Unlike GLP-1 receptor agonists, MICC has no FDA-approved obesity indication and no large Phase 3 weight-loss trials. Lipotropic injections trace their clinical popularity to bariatric-adjacent and wellness-clinic practice rather than to registrational pharmacotherapy data. Individual ingredients have stronger standalone evidence: choline adequate intake recommendations from the Institute of Medicine, inositol RCTs in PCOS, and B12 replacement in documented deficiency states.
Patients should expect MICC to function as adjunctive support, not as a primary weight-loss drug. Meaningful scale movement still depends on caloric deficit, usually GLP-1-mediated appetite reduction plus dietary adherence. Some patients report improved energy or exercise tolerance; others notice minimal subjective change. Honest prescribing frames MICC as a low-risk metabolic add-on with modest, variable benefit rather than a guaranteed accelerator.
Typical dosing and administration
Compounded MICC is commonly prescribed as a weekly intramuscular or subcutaneous injection, though protocols vary by pharmacy and prescriber. Concentrations are pharmacy-specific; patients receive vials with syringes and injection training through telehealth onboarding. Injection site rotation, sterile technique, and sharps disposal follow standard home-injection education. Because MICC is compounded, there is no single FDA-labeled dose, titration and frequency are provider-directed.
Who might consider MICC with GLP-1
- Patients on tirzepatide or semaglutide who report fatigue during dose escalation
- Those with hepatic steatosis or metabolic syndrome markers whose providers want lipotropic hepatic support
- PCOS patients already on GLP-1 who may benefit from inositol-adjacent pathways
- Patients seeking a non-incretin injectable adjunct when metformin is contraindicated or insufficient
MICC is not appropriate as a substitute for GLP-1 in patients who meet pharmacotherapy criteria for obesity. It also does not replace dietary protein, resistance training, or sleep optimization, the structural habits that prevent muscle loss on incretin therapy.
Safety and monitoring
MICC components are generally well tolerated at compounded doses. Methionine excess in rare genetic disorders (homocystinuria) is contraindicated. Choline at very high doses can cause fishy body odor and GI upset. B12 is low-risk but can unmask polycythemia vera in susceptible individuals. Patients on anticoagulation should use careful injection technique to minimize bruising. Liver enzymes and fasting lipids may be monitored in patients with NAFLD/NASH history, though MICC-specific monitoring protocols are not standardized.
Allergic reactions to compounded excipients are possible; patients should report injection-site reactions, urticaria, or systemic symptoms promptly. Pregnancy and breastfeeding data for lipotropic injection cocktails are insufficient, GLP-1 and adjunct decisions in pregnancy require specialist oversight.
Pairing with the GLP-1 stack
In contemporary telehealth obesity practice, MICC often appears in a three-part metabolic stack: GLP-1 or dual incretin for appetite, metformin ER for insulin sensitization in resistant phenotypes, and MICC for lipotropic and B-vitamin support. The combination is empirically popular rather than trial-validated as a fixed trio. Providers should individualize: not every GLP-1 patient needs MICC, and adding injections increases complexity and cost.
CLYR Health offers MICC + B12 as a GLP-1 companion preview SKU for patients whose licensed providers determine lipotropic injection support fits their weight-loss protocol, with ongoing telehealth monitoring consistent with broader metabolic care standards.